United Kingdom Colorectal Cancer Therapeutics Market By Drug Class (Chemotherapy, Immunotherapy, Others), By End User (Hospitals, Clinics, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited Kingdom Colorectal Cancer Therapeutics Market By Drug Class (Chemotherapy, Immunotherapy, Others), By End User (Hospitals, Clinics, Others), By Region, Competition Forecast & Opportunities, 2018-2028F
The United Kingdom Colorectal Cancer Therapeutics Market is expected to witness significant growth during the projected period of 2028. Colorectal cancer, a prevalent public health concern in the United Kingdom, affects the colon or rectum. However, thanks to the country's robust healthcare system and dedicated research and development efforts, advancements in colorectal cancer therapeutics have been achieved. The United Kingdom's colorectal cancer therapeutics market has experienced substantial growth, driven by innovative treatments, targeted therapies, and early detection methods that have revolutionized patient care and improved survival rates.
Colorectal cancer typically originates in the colon (large intestine), where abnormal growths or polyps in the inner lining can lead to the development of cancer. Precancerous polyps can be identified through screening tests performed by healthcare professionals before they progress into cancerous tumors. Timely diagnosis and treatment of colorectal cancer are crucial to prevent its spread to other parts of the body. Fortunately, the implementation of screening tests, early treatment, and innovative therapies has resulted in fewer deaths from colorectal cancer. The United Kingdom's colorectal cancer therapeutics market has witnessed the introduction of various innovative therapies aimed at providing better outcomes and improving patients' quality of life. Notably, targeted therapies have garnered significant attention. By focusing on specific molecular and genetic abnormalities present in cancer cells, targeted therapies offer more precise and effective treatments. Monoclonal antibodies and small molecule inhibitors are examples of such therapies, which have shown promise in improving survival rates and reducing the side effects associated with traditional chemotherapy.
According to the Office for National Statistics, the healthcare cost in the United Kingdom was estimated to be approximately USD350.83 billion in 2022, representing a nominal increase of 0.7% compared to 2021.
Rising Prevalence of Colorectal Cancer Will Spur the Demand for Colorectal Cancer Therapeutics
The United Kingdom is facing a significant burden of colorectal cancer, a devastating disease that claims numerous lives each year. According to the UK Colorectal Cancer Intelligence Hub, colorectal cancer affects over 41,000 people annually in the United Kingdom, with 16,000 deaths resulting from it. The incidence of colorectal cancer has been steadily increasing over the past few decades, attributed to factors such as sedentary lifestyles, unhealthy dietary habits, obesity, and an aging population. Colorectal cancer arises when cells undergo uncontrolled growth and division, similar to other types of cancer. Normally, the body's cells continuously divide, grow, and die, maintaining overall health and functionality. However, in colon cancer, the cells lining the colon and rectum continue to grow and divide instead of dying as they should. These cancerous cells may originate from colon polyps. Improved screening methods and increased awareness have led to early detection, resulting in a higher number of reported cases and expanding the United Kingdom Colorectal Cancer Therapeutics Market. The rising prevalence of colorectal cancer has driven the development and advancement of various treatment modalities within the market, including surgery, radiation therapy, chemotherapy, targeted therapies, immunotherapies, and supportive care. Targeted therapies and immunotherapies, such as monoclonal antibodies and immune checkpoint inhibitors, have revolutionized the treatment landscape by offering more personalized and effective options. Precision medicine has gained significant momentum in the field of colorectal cancer treatment, enabling clinicians to identify specific biomarkers that determine a patient's response to certain therapies through molecular profiling and genetic testing techniques. This approach allows for tailored treatment plans, minimizing unnecessary side effects and optimizing therapeutic outcomes. The increasing availability and affordability of genomic profiling technologies have further facilitated the adoption of precision medicine in the management of colorectal cancer, thereby driving the anticipated growth of the United Kingdom Colorectal Cancer Therapeutics Market in the forecast period.
Rising Geriatric Population Drives the United Kingdom Colorectal Cancer Therapeutics Market
According to the Organization for Economic Co-operation and Development (OECD), the proportion of elderly people in the total population of the United Kingdom is 18.83%.
Recent Developments
- According to the results of a clinical trial funded by Cancer Research UK and conducted by the Universities of Birmingham and Leeds in March 2023, administering chemotherapy to colon cancer patients before surgery has been shown to decrease the likelihood of disease recurrence. The FOxTROT trial revealed that administering the first six weeks of chemotherapy prior to surgery, as opposed to after, reduces the risk of cancer recurrence within two years by 28%.
Mergers and Acquisitions
- In October 2022, a clinical trial partnership and supply agreement between Erasca and Pfizer focused on Palbociclib (Ibrance), a CDK4/6 inhibitor. The aim is to address colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) with KRAS- and NRAS-mutations, through a clinical proof-of-concept trial using ERAS-007 in combination with Palbociclib.
- Furthermore, in March 2023, Pfizer allocated USD43 billion for the acquisition of Seagen, thereby expanding its capabilities in cancer treatment.
- Additionally, in August 2022, Eli Lilly & Company collaborated with ERASCA to investigate the combination of ERAS-601 and Cetuximab for the treatment of metastatic colorectal cancer.
Market Segmentation
United Kingdom Colorectal Cancer Therapeutics Market is segmented into Drug Class, End User, Region and Competitive Landscape. Based on Drug Class, the Market is divided into Chemotherapy, Immunotherapy and Others. Based on End User, the market is categorized into Hospitals, Clinics and Others. Based on region, the United Kingdom Colorectal Cancer Therapeutics Market is segmented into Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
Novartis AG, Pfizer Inc, Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eisai Co., Ltd., Sanofi S.A., Roche Holding AG are some of the key players in the United Kingdom Colorectal Cancer Therapeutics market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, volume forecasting, Company shares, competitive landscape, growth factors, and trends |
| Segments covered | Drug Class End User Region |
| Country scope | Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands |
| Key companies profiled | Novartis AG, Pfizer Inc, Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eisai Co., Ltd., Sanofi S.A., Roche Holding AG |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy